Tardive dyskinesia, marked by involuntary movements due to antipsychotic medication use, faces new treatment horizons. Breakthroughs with Ingrezza and Austedo offer hope by significantly reducing symptoms. Medications like Abilify play roles in both treatment and prevention. Understanding these developments empowers individuals with better management strategies and enhances quality of life for those affected.
Understanding Tardive Dyskinesia
Tardive dyskinesia (TD) is a serious neurological disorder marked by involuntary movements, often caused by prolonged use of antipsychotic medications. These movements may include grimacing, tongue movements, and lip-smacking. The disorder arises primarily as a side effect of prolonged antipsychotic medication use, particularly those associated with first-generation antipsychotics and occasionally observed with newer drugs like Abilify. While considered irreversible until recently, there have been significant advances in treatment options that provide hope for those affected.
Breakthroughs in Treatment: Abilify and Austedo
The development of FDA-approved medications like valbenazine and deutetrabenazine, better known as Ingrezza and Austedo, marked a turning point in the treatment of TD. These drugs deplete neurotransmitters, such as dopamine, within the nerve terminals to help alleviate uncontrolled movements resulting in notable improvements in TD symptoms for many patients. Both medications are VMAT2 inhibitors and have been shown to significantly reduce symptoms as measured by Abnormal Involuntary Movement Scale (AIMS) scores, especially at higher doses.
Austedo: A Convenient Treatment
Austedo XR—a once-daily pill—was approved for treating tardive dyskinesia (TD) and Huntington disease’s chorea. Its availability in diverse dosages allows for broad dosing flexibility, improving its applicability across patients with varying needs. Clinical trials have shown that Austedo can improve TD symptoms in as early as two weeks making it a practical option for managing involuntary movements. This treatment option is reinforced by enduring efficacy and safety demonstrated in long-term clinical trials, making it among the strongest treatment options available today.
Abilify: Preventing and Managing TD
Aripiprazole, sold under the brand name Abilify, is an atypical antipsychotic that acts uniquely as a partial D2 receptor agonist. While its primary application is not specifically for TD, Abilify possesses mechanisms that may lower the onset risk of TD by stabilizing dopamine receptor activity. Evidence shows mixed results on the drug’s effectiveness for treating established TD, but it does offer a lower incidence of tardive dyskinesia compared to older antipsychotics especially due to its unique pharmacological properties. Moreover, Aripiprazole’s partial agonist action at 5-HT1A receptors may increase dopamine release and reduce extrapyramidal side effects.
Important Considerations When Using Treatment
Though the effectiveness of these treatments presents hope for those battling TD, patients must engage in open dialogue with their healthcare providers to determine the best suited course of action. Given that Austedo can interact with other medications such as Depakote, careful attention to possible side effects and drug interactions is necessary. Additionally, since switching medications can introduce new side effects, medical supervision is crucial during any adjustment to safely manage symptoms. Lifestyle adjustments, such as having periodic screenings and possibly integrating supplements like vitamin E, are also supportive measures in managing TD.
Why You Should Learn More About Tardive Dyskinesia Today
Tardive dyskinesia significantly impacts quality of life due to its involuntary movement symptoms, which may affect daily function and social interactions. Understanding how treatments like Abilify and Austedo work to manage and possibly mitigate these symptoms helps individuals stay informed about the best ways to take control of their health outcomes. Improvements stemming from recent breakthroughs in medication mean that those affected now have viable options for achieving better quality of life. Moreover, knowledge of potential side effects and management strategies ensures that patients and their healthcare providers can make informed decisions about care—all vital components for living well with tardive dyskinesia.
Sources
Insight into TD and atypical antipsychotics
Transformative treatments for TD